Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710223 | 0.91 | PTK2B (0.37) | MAP3K5MAPTMAPK1TDP1PTK2B | |
| SCHEMBL6708559 | 0.91 | MAP3K5 (0.38) | MAP3K5MAPTMAPK1TDP1PTK2B | |
| SCHEMBL6710263 | 0.89 | GPR35 (0.36) | MAP3K5MAPTMAPK1TDP1PTK2B | |
| SCHEMBL6708998 | 0.89 | MAP3K5 (0.34) | MAP3K5MAPTMAPK1TDP1PTK2B | |
| SCHEMBL6710241 | 0.86 | GPR35 (0.43) | MAP3K5MAPTMAPK1TDP1GPR35 | |
| SCHEMBL6917364 | 0.86 | GPR35 (0.38) | MAP3K5MAPTMAPK1TDP1PTK2B | |
| SCHEMBL6709908 | 0.86 | GRIK1 (0.36) | MAP3K5MAPTMAPK1TDP1PTK2B | |
| SCHEMBL6712420 | 0.85 | PARP14 (0.38) | MAP3K5MAPTMAPK1TDP1GPR35 | |
| SCHEMBL6708158 | 0.85 | GPR35 (0.38) | MAPTGPR35HIF1ANPSR1RXFP1 | |
| SCHEMBL6711411 | 0.84 | GPR35 (0.42) | MAP3K5MAPTGPR35HIF1ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | MAP3K5 3051/4885MAPT 4754/4885MAPK1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.